SKYE
NASD Skye Bioscience, Inc.$1.68 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.68, and at the day’s high of $1.68
- YTD change
- -71.99%
- vs 20-day SMA
- -6.86%
- vs 200-day SMA
- -69.37%
Price ranges
Price & Performance
+0.97 (+135.16%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.9% away from all-time highs of $155.28
- SKYE is down 72% since the beginning of the year
- SKYE is down 95% over the past 12 months
- SKYE is down 9% over the past 1 month
- 6% of all SKYE investors are betting against SKYE
SKYE reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -64.6%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -1.18%
- vs 8-day SMA
- +1.13%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.